- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Amylyx Pharmaceuticals Inc (AMLX)
Amylyx Pharmaceuticals Inc stock price live, this page displays NASDAQ AMLX stock exchange data. View the AMLX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Amylyx Pharmaceuticals Inc real time stock price chart below.
What Is the Amylyx Pharmaceuticals Inc Stock Price Today?
The Amylyx Pharmaceuticals Inc stock price today is 27.790.
What Is the Stock Symbol for Amylyx Pharmaceuticals Inc?
The stock symbol for Amylyx Pharmaceuticals Inc is "AMLX."
What Stock Exchange Does Amylyx Pharmaceuticals Inc Trade On?
Amylyx Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Amylyx Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Amylyx Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AMLX quote. (ISIN: US03237H1014)
What Is the Amylyx Pharmaceuticals Inc Stock Price Today?
The Amylyx Pharmaceuticals Inc stock price today is 27.790.
What Is the Stock Symbol for Amylyx Pharmaceuticals Inc?
The stock symbol for Amylyx Pharmaceuticals Inc is "AMLX."
What Stock Exchange Does Amylyx Pharmaceuticals Inc Trade On?
Amylyx Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Amylyx Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Amylyx Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AMLX quote. (ISIN: US03237H1014)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
27.640
28.810
52 wk Range
10.830
41.140
AMLX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
27.64028.810
52 wk Range
10.83041.140
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AMLX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
42.364
Upside
+52.44%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
11 Buy
1 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 42.364
(+52.44% Upside)
Amylyx Pharmaceuticals Inc Earnings Call Summary for Q2/2026
- Amylyx reported Q2 2026 adjusted EPS of -$0.39, missing consensus estimate of -$0.35 by 11.43%; shares fell 3.43% premarket to $21.10.
- Company ended quarter with $250.8M in cash, supporting operations into 2028; operating expenses rose 7% YoY to $45.7M amid launch preparations.
- Phase III LUCIDITY trial for avexitide nearing database lock; top-line data expected late August/early September, representing major near-term catalyst.
- Management preparing NDA submission and targeting potential 2027 commercial launch if trial succeeds and FDA approves treatment for post-bariatric hypoglycemia.
- Company advancing pipeline including Wolfram syndrome program, ALS study cohort 3 enrollment, and 2027 IND filing planned for long-acting GLP-1 antagonist AMX0318.
Last Updated: 08/06/2026, 09:10 PM
Read Full TranscriptEarnings
Latest Release
Aug 06, 2026
EPS / Forecast
-0.39 / -0.35
Revenue / Forecast
-- / --
Compare AMLX to Peers and Sector
Metrics to compare | AMLX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAMLXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −22.9x | −0.8x | −0.4x | |
PEG Ratio | −0.56 | −0.63 | 0.00 | |
Price/Book | 14.6x | 4.7x | 2.6x | |
Price / LTM Sales | - | 11.4x | 3.0x | |
Upside (Analyst Target) | 52.4% | 58.8% | 58.2% | |
Fair Value Upside | Unlock | 7.3% | 7.7% | Unlock |
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Amylyx Pharmaceuticals (AMLX) Stock Price Today?
The Amylyx Pharmaceuticals stock price today is 27.790 USD.
What Stock Exchange Does Amylyx Pharmaceuticals Trade On?
Amylyx Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Amylyx Pharmaceuticals?
The stock symbol for Amylyx Pharmaceuticals is "AMLX."
What Is the Amylyx Pharmaceuticals Market Cap?
As of today, Amylyx Pharmaceuticals market cap is 3.490B USD.
What Is Amylyx Pharmaceuticals's Earnings Per Share (TTM)?
The Amylyx Pharmaceuticals EPS (TTM) is -1.431.
When Is the Next Amylyx Pharmaceuticals Earnings Date?
Amylyx Pharmaceuticals will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is AMLX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Amylyx Pharmaceuticals Stock Split?
Amylyx Pharmaceuticals has split 0 times.
How Many Employees Does Amylyx Pharmaceuticals Have?
Amylyx Pharmaceuticals has 136 employees.
What is the current trading status of Amylyx Pharmaceuticals (AMLX)?
As of Oct 04, 2026, Amylyx Pharmaceuticals (AMLX) is trading at a price of 27.790 USD, with a previous close of 27.790 USD. The stock has fluctuated within a day range of 27.640 USD to 28.810 USD, while its 52-week range spans from 10.830 USD to 41.140 USD.
What Is Amylyx Pharmaceuticals (AMLX) Price Target According to Analysts?
The average 12-month price target for Amylyx Pharmaceuticals is 42.364 USD, with a high estimate of 57 USD and a low estimate of 20 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +52.44% Upside potential.
What Is the AMLX Premarket Price?
AMLX's last pre-market stock price is 28.280 USD. The pre-market share volume is 1,210.000, and the stock has decreased by 0.200, or 0.710%.
What Is the AMLX After Hours Price?
AMLX's last after hours stock price is 27.880 USD, the stock has decreased by 0.090, or 0.320%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.